Interview with Jose Manuel Lezama , General Manager, BSN Medical Mexico
When you joined BSN Medical 3 years ago, what was the roadmap set in place for the growth and development of the company? Which opportunities did the company see in…
Address: Asturias 39. Col. Insurgentes Mixcoac Delegacion Benito Juarez C.P. 03920 México City,Mexico
Tel: 52,55,5482,5400
Web: http://mexico.bsnmedical.com/
BSN medical was established in April 2001 as a 50:50 joint venture between Beiersdorf AG, Hamburg, and Smith & Nephew plc, London due to complementary geographic and channel strengths in the areas of wound care, fracture management, physiotherapy and compression therapy. BSN medical was acquired in 2006 by Montagu Private Equity, a leading private equity investor in the European mid-market, with a large pool of available funds, with values ranging from € 100 million to € 1+ billion. Since then, BSN was developed as a fully independent global player in the health care market. Under Montagu’s ownership BSN medical successfully completed 4 acquisitions, further developed the global independency and continued the portfolio upgrade through highly innovative product launches (e.g. Advanced Wound Care).
BSN medical focuses on developing world-class products that offer high quality solutions for both caregivers and patients.
We are one of the world’s leading suppliers in the medical product segments of casting, bandaging, traditional wound care and compression therapy.
When you joined BSN Medical 3 years ago, what was the roadmap set in place for the growth and development of the company? Which opportunities did the company see in…
Arturo Prida Romero, the president of the current National Council of the Partido de la Revolución Democrática (PRD) – one of the main political parties in Mexico – shares the…
Mario Muniz, SVP and GM of IQVIA North LATAM, shares his motivations for joining IQVIA after nearly two decades with pharma and medtech companies, the huge potential of the North…
Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key…
Diego Ruiz, CEO and co-founder of Eseotr3s Pharma shares his entrepreneurial background and the motivation for establishing Eseotr3s Pharma; their focus on flexibility and quality; their international operations and network,…
Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.…
Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing…
David López García, Mexico country manager of global rare genetic therapy player Biomarin, outlines the challenging situation around patient access to orphan drugs in Mexico and the importance of building…
Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares the many new initiatives the Institute has introduced in the past couple…
In the historic year of their 70th anniversary, Cristóbal Thompson, executive director of the Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIIF), the association for research-based pharmaceutical companies in Mexico,…
Rafael Gual Cosío, director general of the Cámara Nacional de la Industria Farmacéutica (CANIFARMA), the umbrella industry association for the healthcare sector in Mexico, shares his perspectives on the complex…
The election of populist President Andres Manuel Lopez Obrador (AMLO) on 1 July 2018 heralded a new era of hope and optimism for Mexicans. In the first 13 months of…
Juan de Villafranca, executive director of the Asociacion Mexicana de Laboratorios Farmaceuticos (AMELAF), shares the exciting new initiatives he has launched in the past two years of his term; the…
See our Cookie Privacy Policy Here